Biologics Segment is the largest segment driving the growth of Biopharma Buffer Market
The global Biopharma Buffer Market is estimated to be valued at US$ 3.68 Bn or Mn in 2023 and is expected to exhibit a CAGR of 7.1% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Biopharma buffers are solutions used to maintain and stabilize the PH of biopharmaceutical products during manufacturing, transportation and storage. They help in maintaining optimal conditions for cell growth and drug stability.
Market key trends:
One of the key trends in the biopharma buffer market is the development of specialized buffers for different biopharmaceutical applications. Manufacturers are developing proprietary formulations tailored for specific needs such as cell culture media, purification buffers, transportation and storage buffers. They contain unique blends of acids, salts and other excipients optimized for attributes like buffering capacity, tonicity and solubility. This enables consistent and reliable performance under varied conditions.
Market key trends:
The Global Biopharma Buffer Market has been witnessing significant demand due to the increasing R&D investments in drug development by biopharmaceutical companies. Biopharma buffer solutions play a crucial role in maintaining optimum pH levels which is necessary for stabilizing biological molecules like proteins, antibodies etc. during various downstream and upstream processes. Growing adoption of single-use technologies by biopharma manufacturers to minimize costs and improve flexibility has also fueled the need for buffer solutions. Continued progress in cell and gene therapy development is another factor driving increased uptake of buffer solutions in the industry.
SWOT Analysis
Strength: Growing biologics drug pipeline and rising demand for antibody drugs and vaccines boost the biopharma buffer market.
Weakness: High costs associated with buffer production can hamper market growth.
Opportunity: Increasing preference for single-use technologies by biopharmas present an opportunity.
Threats: Stringent regulations pertaining to buffer validation can challenge market players. Uncertain regulatory guidelines across regions is another threat.
Key Takeaways
The global biopharma buffer market size was valued at US$ 3.68 Bn in 2023. The market is expected to grow at a CAGR of 7.1% during the forecast period due to increasing R&D investments in drug development.
Regional analysis: North America dominated the global market in 2023 owing to presence of major players and rapid uptake of novel biologic drugs. Asia Pacific is anticipated to witness fastest growth over the forecast period supported by emerging biopharmaceutical industry and growing biologics pipeline.
Key players: Key players operating in the biopharma buffer market are Merck KGaA, Thermo Fisher Scientific Inc., Avantor, Inc., Lonza Group Ltd., Bio-Rad Laboratories, Inc., Sartorius AG, Corning Inc., Becton, Dickinson and Company, GE Healthcare, Promega Corporation.
Read More: https://cmiresearch.blogspot.com/2023/11/the-growing-demand-for-cleaner-fuel-is.html
English
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian